Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03LJR
|
|||
| Former ID |
DAP000663
|
|||
| Drug Name |
Sirolimus
|
|||
| Synonyms |
53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90; ICD-9: 203] | Approved | [1], [2] | |
| Organ transplant rejection [ICD-11: NE84; ICD-9: 279.5, 996] | Approved | [3], [4] | ||
| Dutch elm disease [ICD-11: 8D64; ICD-10: B81-B83] | Phase 1/2 | [3], [4] | ||
| Therapeutic Class |
Immunosuppressive Agents
|
|||
| Company |
Wyeth
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C51H79NO13
|
|||
| Canonical SMILES |
CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC
|
|||
| InChI |
1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1
|
|||
| InChIKey |
QFJCIRLUMZQUOT-HPLJOQBZSA-N
|
|||
| CAS Number |
CAS 53123-88-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
636884, 830671, 7890221, 7982025, 8145920, 11110132, 11110134, 11110139, 11528741, 12014635, 14816423, 14816426, 24430811, 24899339, 26701762, 26705530, 26705537, 26709840, 26713306, 37101833, 46391895, 46392864, 47289337, 48416541, 49635682, 49815675, 50103901, 50139515, 56310631, 56310880, 56311583, 56311585, 56311714, 56311827, 56311949, 56311983, 56312137, 56312183, 56312184, 56312185, 56312186, 56312645, 56312887, 56313330, 56313354, 56313375, 56313498, 56313803, 56313974, 56314022
|
|||
| ChEBI ID |
CHEBI:9168
|
|||
| ADReCS Drug ID | BADD_D02028 | |||
| SuperDrug ATC ID |
L04AA10
|
|||
| SuperDrug CAS ID |
cas=053123889
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002452) | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6031). | |||
| REF 4 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 5 | The genomic landscape of nasopharyngeal carcinoma.Nat Genet. 2014 Aug;46(8):866-71. | |||
| REF 6 | An orthotopic model of metastatic nasopharyngeal carcinoma and its application in elucidating a therapeutic target that inhibits metastasis.Genes Cancer. 2011 Nov;2(11):1023-33. | |||
| REF 7 | Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma.Cancer Res. 2004 Aug 1;64(15):5251-60. | |||
| REF 8 | Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.